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BALANCING EFFICACY AND SAFETY OF PRASUGREL VS. 
CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS 
UNDERGOING PERCUTANEOUS CORONARY INTERVENTION:  
A POPULATION ANALYSIS OF NET CLINICAL BENEFIT
Schmitt C1, McCollam PL2, Creveling TL2, Oberdiek A3
1Eli Lilly and Company, Windlesham, Surrey, UK, 2Eli Lilly and Company, Indianapolis, IN, 
USA, 3Daiichi Sankyo Europe GmbH, Munich, Germany
OBJECTIVES: TRITON-TIMI-38 showed reduction in atherothrombotic events 
with more intensive antiplatelet therapy with prasugrel versus clopidogrel, but with 
more bleeding. Patients without prior TIA/stroke, patients without any of 3 risk 
factors for bleeding (prior TIA/stroke, age q75 years, weight  60 kg) and patients 
with STEMI tended to have greater net clinical beneﬁt. This analysis aims at determin-
ing which therapeutic strategy would optimize clinical outcomes in a real-life popula-
tion with acute coronary syndrome (ACS) undergoing percutaneous coronary 
intervention (PCI) in Europe. METHODS: Published estimates from TRITON-TIMI-
38 were used to predict clinical outcomes in a hypothetical population of 10,000 
ACS-PCI patients. Strategies analysed were: clopidogrel for all (A), prasugrel for 
patients without prior TIA/stroke and clopidogrel for others (B), prasugrel for patients 
without prior TIA/stroke, age 75 years and weight q60 kg, clopidogrel for others 
(C), prasugrel for patients with STEMI, clopidogrel for others (D). Subgroup sizes 
were derived from the APTOR observational study of 1,525 ACS-PCI patients 
recruited in Spain, UK and France in 2007. RESULTS: Of 10,000 ACS-PCI patients, 
9,784 would have no prior TIA/stroke, 7,797 would have none of the bleeding 
risk factors above, 3,816 would have STEMI. Strategy A would result in 1,205 ath-
erothrombotic events (composite endpoint of cardiovascular death, MI, stroke), 
182 major haemorrhage events and 1,385 net clinical outcome events (composite 
endpoint of all cause death, MI, stroke or major haemorrhage). Alternative strategies 
would result in incremental events of, respectively, 245, 49 and 196 (B), 211, 
39 and 179 (C), 92, 11 and 92 (D). CONCLUSIONS: This model suggests 
prasugrel has a broad place in therapy based on net clinical beneﬁt. Signiﬁcantly 
restricted use would prevent disproportionately fewer atherothrombotic events relative 
to bleeding events. This model may be used to assist health care decision makers, along 
with other decision-analysis tools, in making recommendations for optimal use of 
clopidogrel and prasugrel.
PCV29
OUTCOMES ASSESSMENT IN LOW & HIGH RISK P.T.C.A. PATIENTS
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OBJECTIVES: The study made an attempt to correlate the costs and health outcomes 
of the patients who had undergone Percutaneous Transluminal Coronary Angioplasty 
(PTCA) with stenting. METHODS: This retrospective study analysed 258 patients 
who had undergone PTCA with stenting. Patients were divided into two groups: 1) 
those with low risk factors (0–2); 2) those with high risk factors (2). Costs and risk 
factors were identiﬁed. Outcomes like average length of stay (LOS) [average intensive 
care unit (ICU), non-ICU, post-operative, total LOS)], post surgical survival, post 
surgical complications, number of readmissions within 1 year for both the groups of 
patients with low and high risk factors in PTCA were assessed. RESULTS: The cost 
for PTCA [in lakhs o standard error of mean (SEM)] was higher in the patients with 
high risk factors (3.23 o 0.16 lakhs) as compared to the patients with low risk factors 
(2.75 o 0.07 lakhs). The patients with high risk factors had a longer LOS (ICU, non-
ICU, post-operative and total LOS), slightly lower survival rate, higher incidence of 
post surgical complications and higher readmission rate within 1 year as compared to 
the patients with low risk factors. A total of 72 (approx. 30%) patients who under-
went PTCA with stenting were readmitted within 1 year. Reasons for readmissions 
within one year were determined. On readmission, PTCA with stenting were per-
formed in 36% of patients, followed by coronary angiography (33%), medical man-
agement (28%), and coronary artery by-pass grafting (3%). CONCLUSIONS: High 
risk patients had a longer length of stay, higher incidence of post surgical complica-
tions, poorer survival and higher readmission rate. These results have provided an 
insight into the costs and outcomes associated with PTCA and will help patients as 
well as interventionists in decision making regarding allocation of resources for a 
speciﬁc groups or subgroups of patient population.
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PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY 
SYNDROME PATIENTS IN 2008: CZECH REPUBLIC BASELINE RESULTS 
FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II 
(APTOR II)
Coufal Z1, Norrbacka K2, Hronkova M3, Paget MA4, Sartral M4, Schmitt C2
1Bata regional Hospital, Zlin, Czech Republic, 2Eli Lilly and Company Ltd, Windlesham, 
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OBJECTIVES: This analysis aims to explore management of acute coronary syn-         
dromes (ACS) from acute event to hospital discharge in Czech Republic, and to 
measure Quality of Life (QoL) at discharge. METHODS: This 12-month international   
prospective, observational study recruited ACS patients undergoing percutaneous 
coronary intervention (PCI), April–November 2008, capturing practice patterns, 
resource use and QoL. RESULTS: A total of 507 eligible ACS-PCI patients were        
included: median age 61 (IQR 54–69), median weight 84 (IQR 75–95), 24% female, 
23% Type-2 diabetics, and 16% prior myocardial infarction (MI). Index diagnosis 
was: unstable angina or non-ST-elevation MI (UA/NSTEMI)-43% and ST-elevation 
MI (STEMI)-57%. Almost all patients (97%) were implanted with stents: 83% bare 
metal stents (BMS) only, 14% drug eluting stents (DES) only and 3% both. Time from 
ACS event to PCI was 3 days or less for 80% of UA/NSTEMI patients and 1 day or                
less for 97% of STEMI patients. Antiplatelet loading oral medications used: aspirin-
84% and clopidogrel-98% (no use of ticlopidine). Clopidogrel loading dose (LD) was     
administered in catheterization lab-26%, previous hospital-22%, ambulance-19%, 
coronary care unit-19%, emergency room-6%, intensive care unit-3%, and other 
ward-5% and near PCI (previous 6 hours, during PCI, following 6 hours) in 87% of 
cases. Total clopidogrel LD was above 300 mg in 56% of cases and in-hospital main-        
tenance dose (MD) was 75 mg in 99%. At time of hospital discharge, 98% of patients            
were receiving clopidogrel (discharge dose 75 mg in all cases) and QoL was good:         
median EQ-5D health state index at 1.00 (IQR 0.80–1.00). CONCLUSIONS: These 
real life data reﬂect treatment patterns among ACS patients managed by PCI in Czech 
Republic in 2008. Time from ACS to PCI is very low especially in patients with 
STEMI. During PCI, DES are implanted six times less often than BMS. The QoL of 
patients at discharge was high.
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LONGITUDINAL ASSESSMENT OF LIPID ABNORMALITIES IN A SAMPLE 
OF ITALIAN PATIENTS: PREVALENCE AND ATTAINMENT OF GOAL/
NORMAL LEVELS
Ambegaonkar BM1, Heiman F2, Soro M3, Sazonov V1
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OBJECTIVES: The objective of this study was to evaluate attainment of goal/normal 
lipid levels and predictors thereof following lipid modifying therapy (LMT). 
METHODS: Using CSD LPD database we identiﬁed patients age 18 who initiated 
LMT between January 1, 2004-October 1, 2006, had a complete lipid proﬁle (LDL-C,           
HDL-C and TG) 1 year pre and post index date and continued LMT for q9 months. 
High risk population was classiﬁed as those with CHD, diabetes or 10-year CHD risk 
20%. Guidelines recommended by the current European Society of Cardiology were 
used to deﬁne threshold levels for elevated LDL-C, low HDL-C and elevated TGs. 
RESULTS: Among 524 patients (63% high risk), 93% had elevated LDL-C, 22% had 
low HDL-C and 62% had elevated TGs before therapy. Additionally, 67% experi-
enced low HDL-C and/or elevated TG irrespective of LDL-C levels. Post therapy (93% 
on statins), 53% had elevated LDL-C (48% among high risk), 25% had low HDL-C 
(26% among high risk) and 43% had elevated TGs (39% among high risk). Low 
HDL-C and/or elevated TG were observed among 54% (52% among high risk). 
Obesity, presence of diabetes and lower baseline LDL-C were associated with better 
LDL-C goal attainment while attainment of normal TG level was associated with 
presence of hypertension and lower baseline TG. Patients with higher baseline HDL-C 
and older female patients were more likely to attain HDL-C normal level, while female 
patients with CHD risk 20% were less likely to reach HDL-C normal level. CON-
CLUSIONS: In this longitudinal study of Italian patients, following therapy (where 
statins were primarily urilized), additional 40% of patients achieved LDL-C goal and 
additional 19% reached normal triglyceride levels, while no improvement was 
observed in HDL-C levels where additional 3% had low HDL-C. In addition to 
baseline lipid levels, certain CV risk factors were strong predictors for goal/normal 
level attainment of each lipid parameter.
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A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID 
DISORDERS AMONG FRENCH PATIENTS IN PRIMARY CARE
Laforest L1, Ambegaonkar BM2, Souchet TP3, Sazonov V2, Van Ganse E4
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OBJECTIVES: This cross-sectional study attempted to identify the extent of preva-
lence of low high density lipoprotein cholesterol (HDL-C) and/or elevated triglycerides 
(TG) combined with elevated low density lipoprotein cholesterol (LDL-C) among 
statin treated patients in French clinical practice. METHODS: Using BKL-THALES 
database we identiﬁed patients who were treated with a statin for at least six months 
and also had a complete lipid proﬁle (LDL-C, HDL-C and TG) within the past six 
months. Patients were considered to be at high CV risk if they had a history of CV 
disease, diabetes or 10 year CHD risk q20 %. National guidelines in France (AFSSAPS) 
were used to deﬁne lipid threshold levels. Based on these guidelines, HDL-C and TG 
threshold levels were q0.40 g/l and   a1.5 g/l whereas, LDL-C threshold levels were       
identiﬁed as a2.2 g/l, a1.9 g/l, a1.6 g/l, a1.3 g/l or a1.0 g/l depending on the number 
of risk factors and the level of CV risk. RESULTS: In a sample of 2544 patients treated 
with statins (93% as monotherapy), approximately 51% patients (n  1292) experi-
enced q1 lipid abnormalities. Among these, 55% had elevated LDL-C while approxi-
mately 25% had elevated LDL-C along with HDL-C and/or TG abnormality. Nearly 
half (n  1201) of the sample were high CV risk patients with 71% (n  854) experi-
encing q1 lipid abnormalities. Among the latter, prevalence of elevated LDL-C was 
72%, while nearly one-third experienced low HDL-C and/or elevated TG combined 
with elevated LDL-C. CONCLUSIONS: In this cross-sectional study of French 
patients treated with statins, over half of all patients (approximately upto three-
quarter among high CV risk) with at least one lipid abnormalities experienced elevated 
LDL-C. In addition, up to one-third of high CV risk patients experienced low HDL-C 
and/or elevated TG disorders along with elevated LDL-C and could potentially beneﬁt 
from other lipid-modifying therapies besides statins.
